西黄丸联合PP化疗方案治疗痰瘀互结型非小细胞肺癌患者的效果  

Efficacy of xihuangwan combined with PP regimen in treatment of non-small cell lung cancer with phlegm and stasis interconnection

作　　者：卢佳伟 李金红[2] 陈光 刘迪 马志斌 杨承睿 刘增 刘非 李博瑶[4] Lu Jia-wei;Li Jin-hong;Cheng Guang;Liu Di;Ma Zhi-bin;Yang Chen-rui;Liu Zeng;Liu Fei;Li Bo-yao(Graduate School,Hebei University of Traditional Chinese Medicine,Shijiazhuan 050091,China;Department of Radiotherapy and Chemotherpy,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Cangzhou 061013,China;Graduate School,Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China;College of Traditional Chinese Medicine,North China University of Technology,Tangshan 063210,China)

机构地区：[1]河北中医药大学研究生学院,石家庄050091 [2]河北省沧州中西医结合医院放化疗科,沧州061013 [3]成都中医药大学研究生学院,成都610072 [4]华北理工大学中医学院,唐山063210

出　　处：《中国药物应用与监测》2025年第1期111-115,共5页Chinese Journal of Drug Application and Monitoring

基　　金：河北省2022年度中医药类科研计划项目(2022247)。

摘　　要：目的观察西黄丸联合PP化疗方案(培美曲塞+顺铂)治疗痰瘀互结型非小细胞肺癌的临床效果及安全性。方法选取2022年1月至2024年6月河北省沧州中西医结合医院予以针对性治疗的痰瘀互结型非小细胞肺癌患者87例,采用随机数字表法分为两组。对照组43例患者予以PP化疗方案治疗,研究组44例患者另外加服西黄丸治疗。对比两组患者临床疗效、中医证候积分、血清肿瘤标志物水平、免疫功能水平及不良反应发生情况。结果研究组客观缓解率和疾病控制率分别为52.27%(23/44)和84.09%(37/44),高于对照组的30.23%(13/43)和60.47%(26/43)(χ^(2)=4.355、6.077,均P<0.05);治疗后,研究组中医证候积分[(6.89±1.24)分]低于对照组[(8.67±1.45)分](t=6.159,P<0.05)。治疗后,研究组血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及细胞角蛋白19片段抗原21-1(CYFRA21-1)水平[分别为(23.34±3.56)ng·L^(-1)、(25.12±3.76)μg·L^(-1)、(3.23±0.48)ng·L^(-1)]均低于对照组[分别为(27.45±3.78)ng·L^(-1)、(28.90±4.28)μg·L^(-1)、(3.75±0.53)ng·L^(-1)](t=5.222、4.379、4.799,均P<0.05)。治疗后,研究组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平[分别为(61.45±4.12)%、(39.46±2.15)%、(1.54±0.23)]均高于对照组[分别为(56.32±4.47)%、(36.26±2.48)%、(1.27±0.25)](t=5.568、6.435、5.224,均P<0.05)。研究组恶心呕吐、血小板减少、肝肾功能损伤及白细胞减少等发生概率相较于对照组更低(χ^(2)=7.228、4.506、5.213、3.941,均P<0.05)。结论西黄丸联合PP化疗方案治疗痰瘀互结型非小细胞肺癌的效果显著,可有效改善患者症状和免疫功能,降低肿瘤标志物水平,并减少不良反应。Objective To observe the clinical efficacy of xihuangwan combined with PP regimen(pemetrexed+cisplatin)in the treatment of non-small cell lung cancer(NSCLC)with phlegm and stasis interconnection and investigate its safety.Methods Eighty-seven patients with non-small cell lung cancer of the phlegm and stasis interconnection type admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2022 to June 2024 were selected and randomly divided into 2 groups.The 43 patients in the control group were given PP regimen chemotherapy,and those 44 patients in the study group were given xihuangwan oral treatment on the basis of the regimen in the control group.The clinical efficacy,TCM evidence points,serum tumour marker levels,immune function levels and the occurrence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate of the study group were 52.27%(23/44)and 84.09%(37/44),respectively,which were higher than those of the control(30.23%(13/43)and 60.47%(26/43))(χ^(2)=4.355,6.077,P<0.05).They were lower in the study group((6.89±1.24)points)than in the control((8.67±1.45)points)(t=6.159,P<0.05).Serum CEA,NSE,and CYFRA21-1 levels in the study group after treatment were(23.34±3.56)ng·L^(-1),(25.12±3.76)μg·L^(-1),(3.23±0.48)ng·L^(-1),respectively,and they were lower than those of the control((27.45±3.78)ng·L^(-1),(28.90±4.28)μg·L^(-1),(3.75±0.53)ng·L^(-1))(t=5.222,4.379,4.799,all P<0.05).CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)levels of the study group were(61.45±4.12)%,(39.46±2.15)%,(1.54±0.23),respectively,which were higher than those of the control((56.32±4.47)%,(36.26±2.48)%,(1.27±0.25),respectively)(t=5.568,6.435,5.224,P<0.05).The incidence of adverse reactions such as nausea and vomiting,thrombocytopenia,leucopenia and hepatic and renal impairment of the study group were lower than those of the control(χ^(2)=7.228,4.506,5.213,3.941,all P<0.05).Conclusion The efficacy of xihuangwan combined with PP regim

关 键 词：非小细胞肺癌 痰瘀互结型 西黄丸 肿瘤标志物 免疫功能 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]